Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Mol Clin Oncol ; 18(5): 44, 2023 May.
Artigo em Inglês | MEDLINE | ID: mdl-37090744

RESUMO

The present study aimed to evaluate the rate of positive surgical margins for magnetic resonance imaging (MRI) performed in the supine position prior to breast-conserving surgery (BCS). The rate of positive surgical margins and the clinicopathological factors were examined in consecutive patients with BCS who underwent preoperative MRI performed in the supine position at Sapporo Medical University Hospital (Sapporo, Japan) and related hospitals and clinics between January 2012 and December 2013. Of 1,175 eligible patients, 1,150 were included after excluding 25 patients with either bilateral breast cancer or stage IV disease. Positive margin was defined as no cancer seen on the resected margin. The primary endpoint was the rate of positive surgical margins when preoperative MRI was performed in the supine position and the secondary endpoint was identification of the factors that predict positive margins. Of the 1,150 female patients (median age, 55 years; range, 29-97 years) who underwent BCS for breast cancer following MRI performed in the supine position, 215 (18.8%) had positive margins, which is similar to the rate with MRI in the prone position, and 930 (81.2%) had negative margins. The rate of positive surgical margins in patients of the human epidermal growth factor receptor 2 (HER2) type was significantly higher than that in the non-HER2 type group (6.5 and 2.9%; χ2 P=0.0103). There was no increase in the rate of positive margins in breast cancers with a diameter of >T2. The rate of positive surgical margins following MRI performed in the supine position was 18.8%. Supine MRI appears to be suitable for informing on the extent of resection of breast cancer.

2.
Exp Ther Med ; 25(1): 68, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36605524

RESUMO

The proper use of anthracycline-containing regimens in combination with anti-HER2-targeted therapy in a neoadjuvant setting for patients with HER2-positive breast cancer has not been resolved. Regimens preceded by anthracyclines have become the standard of care, and although the order has no significant impact on HER2-negative breast cancer, it is inconclusive as to whether a taxane-first sequence would have a similar effect on HER2-positive breast cancer. The present study aimed to investigate the benefit of a taxane-first sequence and of adriamycin and cyclophosphamide (AC) in patients with non-clinical complete response (non-cCR) to pertuzumab, trastuzumab and docetaxel (PTD). The present single-center prospective observational study was performed to investigate PTD followed by AC, and aimed to clarify the cCR rate after PTD alone and the pathological clinical response (pCR) rate after subsequent AC in patients without cCR after PTD alone. A total 24 patients were analyzed; of these, 14 achieved pCR (pCR rate, 58.3%). While four of 14 patients (28.6%) in the intention-to-treat population achieved pCR, nine of 14 patients (64.3%) achieved pCR with AC but not cCR after PTD. The median tumor reduction rate after four cycles of PTD was 58.9% (range, 20.8-100%) in all 24 patients, whereas the reduction rate after PTD-AC was 76.9% (range, 31.1-100%). Cardiac serious adverse events occurred in three patients (12.5%). In conclusion, a high pCR rate was observed for the taxane-first sequence. Patients were highly responsive to PTD, but some cases achieved additional antitumor effects after AC, which resulted in pCR without cCR after PTD alone. Since cardiotoxicity remains a significant problem, a higher risk-benefit treatment strategy is required to aim for AC omission. Trial registration number: UMIN000046338, name of registry: UMIN-CTR, date of registration: December 10, 2021.

3.
J Surg Res ; 267: 267-273, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34171562

RESUMO

BACKGROUND: In clinical practice, drains had been routinely used for reducing seroma formation after breast surgery. However, an optimal timing to remove drains does not identify yet. METHODS: This study aimed to compare the clinical outcome, such as seroma formation, surgical site infection (SSI), and a length of hospital stay between early removal and late removal. A systematic review was performed using PubMed, MEDLINE, and the Cochrane Library. Breast cancer patients who received surgery using drains were eligible. Those parameters were compared between early vs late removal. RESULTS: Eleven studies included in this meta-analysis. Seroma formation in the early removal group was significantly higher than the one in the late removal group (RR = 1.58: 95%CI [1.25-2.01], P = 0.0001), meanwhile no significant difference was found among the groups for SSI (RR = 0.82: 95%CI [0.51-1.31], P= 0.40). A length of hospital stay in the early removal group was also significantly shorter than late removal (RR -3.31: 95%CI [-5.13-1.49], P = 0.0004). CONCLUSIONS: Seroma formation was significantly higher in patients who had early drain removal. Conversely, SSI incidence was low, and early removal did not increase SSI incidence. In conclusion, early drain removal has no proved clinical benefit in these settings besides reduction of hospital stays.


Assuntos
Neoplasias da Mama , Drenagem , Neoplasias da Mama/cirurgia , Drenagem/efeitos adversos , Feminino , Humanos , Tempo de Internação , Mastectomia/efeitos adversos , Seroma/epidemiologia , Seroma/etiologia , Seroma/prevenção & controle , Infecção da Ferida Cirúrgica/epidemiologia , Infecção da Ferida Cirúrgica/etiologia , Infecção da Ferida Cirúrgica/prevenção & controle
4.
J Immunother ; 32(5): 474-85, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19609239

RESUMO

Identification of tumor-associated antigens may facilitate vaccination strategies to treat patients with malignant diseases. We have found that the centrosomal protein, Cep55/c10orf3 acts as a novel breast carcinoma-associated tumor-associated antigen. Cep55/c10orf3 mRNA was detectable in a wide variety of tumor cell lines. Expression was barely detectable in normal tissues except for testis and thymus. Moreover, Cep55/c10orf3 protein could be detected by a monoclonal anti-Cep55/c10orf3 antibody (# 11-55) in 69.8% of breast carcinoma, 25% of colorectal carcinoma, and 57.8% of lung carcinoma tissues. The expression of Cep55/c10orf3 protein did not show any relationship with the hormone receptors such as estrogen receptor and progesterone receptor or expression patterns of p185 HER2/neu. We designed 11 peptides which displayed a human leukocyte antigen-A24 binding motif. One Cep55/c10orf3-peptide, Cep55/c10orf3_193(10) (VYVKGLLAKI), induced cytotoxic T lymphocytes (CTLs) in 3 of 3 patients with Cep55/c10orf3 (# 11-55)-positive breast carcinoma. A Cep55/c10orf3_193(10)-specific CTL clone could also recognize Cep55/c10orf3 (+) displayed on human leukocyte antigen-A24 (+) cancer cell lines. These data indicate that Cep55/c10orf3 peptides were naturally presented by breast cancer cells and can cause CTL clonal expansion in vivo. Monoclonal antibody # 11-55 and the Cep55/c10orf3_193(10) peptides may be useful as part of a therapeutic strategy for hormonal therapy or anti-p185 HER2/neu monoclonal antibody therapy-resistant breast carcinoma patients.


Assuntos
Neoplasias da Mama/imunologia , Neoplasias da Mama/terapia , Proteínas de Ciclo Celular/imunologia , Proteínas de Ciclo Celular/metabolismo , Imunoterapia Ativa , Proteínas Nucleares/imunologia , Proteínas Nucleares/metabolismo , Fragmentos de Peptídeos/metabolismo , Linfócitos T Citotóxicos/metabolismo , Antígenos de Neoplasias/imunologia , Neoplasias da Mama/patologia , Centrossomo/metabolismo , Clonagem Molecular , Resistencia a Medicamentos Antineoplásicos , Feminino , Perfilação da Expressão Gênica , Células HCT116 , Antígenos HLA-A/metabolismo , Antígeno HLA-A24 , Humanos , Imuno-Histoquímica , Células K562 , Análise em Microsséries , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/genética , Fragmentos de Peptídeos/imunologia , Ligação Proteica , Domínios e Motivos de Interação entre Proteínas/imunologia , Transporte Proteico , Linfócitos T Citotóxicos/imunologia , Linfócitos T Citotóxicos/patologia
5.
J Transl Med ; 6: 24, 2008 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-18471305

RESUMO

BACKGROUND: We previously reported that survivin-2B, a splicing variant of survivin, was expressed in various types of tumors and that survivin-2B peptide might serve as a potent immunogenic cancer vaccine. The objective of this study was to examine the toxicity of and to clinically and immunologically evaluate survivin-2B peptide in a phase I clinical study for patients with advanced or recurrent breast cancer. METHODS: We set up two protocols. In the first protocol, 10 patients were vaccinated with escalating doses (0.1-1.0 mg) of survivin-2B peptide alone 4 times every 2 weeks. In the second protocol, 4 patients were vaccinated with the peptide at a dose of 1.0 mg mixed with IFA 4 times every 2 weeks. RESULTS: In the first protocol, no adverse events were observed during or after vaccination. In the second protocol, two patients had induration at the injection site. One patient had general malaise (grade 1), and another had general malaise (grade 1) and fever (grade 1). Peptide vaccination was well tolerated in all patients. In the first protocol, tumor marker levels increased in 8 patients, slightly decreased in 1 patient and were within the normal range during this clinical trial in 1 patient. With regard to tumor size, two patients were considered to have stable disease (SD). Immunologically, in 3 of the 10 patients (30%), an increase of the peptide-specific CTL frequency was detected. In the second protocol, an increase of the peptide-specific CTL frequency was detected in all 4 patients (100%), although there were no significant beneficial clinical responses. ELISPOT assay showed peptide-specific IFN-gamma responses in 2 patients in whom the peptide-specific CTL frequency in tetramer staining also was increased in both protocols. CONCLUSION: This phase I clinical study revealed that survivin-2B peptide vaccination was well tolerated. The vaccination with survivin-2B peptide mixed with IFA increased the frequency of peptide-specific CTL more effectively than vaccination with the peptide alone, although neither vaccination could induce efficient clinical responses. Considering the above, the addition of another effectual adjuvant such as a cytokine, heat shock protein, etc. to the vaccination with survivin-2B peptide mixed with IFA might induce improved immunological and clinical responses.


Assuntos
Neoplasias da Mama/imunologia , Neoplasias da Mama/terapia , Vacinas Anticâncer/uso terapêutico , Carcinoma/imunologia , Carcinoma/terapia , Proteínas Associadas aos Microtúbulos/imunologia , Proteínas de Neoplasias/imunologia , Adulto , Idoso , Formação de Anticorpos/fisiologia , Neoplasias da Mama/patologia , Vacinas Anticâncer/imunologia , Carcinoma/patologia , Feminino , Humanos , Imunoterapia , Proteínas Inibidoras de Apoptose/imunologia , Proteínas Associadas aos Microtúbulos/química , Pessoa de Meia-Idade , Proteínas de Neoplasias/química , Fragmentos de Peptídeos/imunologia , Recidiva , Testes Sorológicos , Survivina
6.
Breast Cancer ; 13(4): 340-3, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17146159

RESUMO

Sappey's demonstration of the breast lymphatic vessels, showing the presence of a subareolar lymphatic plexus and few thick vessels originating from the breast itself, is famous. However, with the exception of such studies performed by injection methods, to the best of our knowledge there has been no demonstration of the entire distribution of the breast lymphatic vessels. D2-40 immunohistochemistry of semiserial sections (at 0.1-mm intervals) taken from the healthy breast of a 20-year-old female cadaver revealed that the lymphatic endothelial density was much higher in and along the mammary glandular tissues than in the overlying subcutaneous and deep fascial tissues. Thus, the extent of the subareolar lymphatic plexus is likely to have been overestimated by the injection method. Instead, networks of lymphatic vessels around the mammary glands were evident in the physiological state.


Assuntos
Mama/patologia , Endotélio Linfático/patologia , Glândulas Mamárias Humanas/patologia , Adulto , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais Murinos , Cadáver , Contagem de Células , Feminino , Humanos , Imuno-Histoquímica , Tela Subcutânea/patologia
7.
Expert Opin Biol Ther ; 5(6): 799-807, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15952910

RESUMO

Recently, the number of patients with colorectal cancer has been increasing. Although most patients with early colorectal cancer have a good prognosis, in the case of recurrent or metastatic disease, the prognosis is poor and most patients will ultimately die of cancer. Furthermore, the conventional treatment, such as chemotherapy or radiation therapy, occasionally can not be continued due to reasons of toxicity and/or poor response. Therefore, novel therapeutic optional approaches based on immunotherapy are being explored at present. This review describes and sums up the principles and the longstanding problems of peptide vaccine therapy, and demonstrates the results of clinical trials with colorectal cancer peptide vaccine therapy, including the authors' personal appraisal. In conclusion, the future prospects of peptide vaccine therapy are described.


Assuntos
Vacinas Anticâncer/uso terapêutico , Neoplasias Colorretais/terapia , Vacinas de Subunidades Antigênicas/uso terapêutico , Adjuvantes Imunológicos/uso terapêutico , Vacinas Anticâncer/efeitos adversos , Ensaios Clínicos como Assunto , Neoplasias Colorretais/imunologia , Monitoramento de Medicamentos , Previsões , Humanos , Linfócitos T/imunologia
8.
J Transl Med ; 2(1): 19, 2004 Jun 13.
Artigo em Inglês | MEDLINE | ID: mdl-15193151

RESUMO

Survivin is a member of the inhibitor of apoptosis protein (IAP) family containing a single baculovirus IAP repeat domain. It is expressed during fetal development but becomes undetectable in terminally differentiated normal adult tissues. We previously reported that survivin and its splicing variant survivin-2B was expressed abundantly in various types of tumor tissues as well as tumor cell lines and was suitable as a target antigen for active-specific anti-cancer immunization. Subsequently, we identified an HLA-A24-restricted antigenic peptide, survivin-2B80-88 (AYACNTSTL) recognized by CD8+ cytotoxic T lymphocytes (CTLs). We, therefore, started a phase I clinical study assessing the efficacy of survivin-2B peptide vaccination in patients with advanced or recurrent colorectal cancer expressing survivin. Vaccinations with survivin-2B peptide were given subcutaneously six times at 14-day intervals. Of 15 patients who finished receiving the vaccination schedule, three suffered slight toxicities, including anemia (grade 2), general malaise (grade 1), and fever (grade 1). No severe adverse events were observed in any patient. In 6 patients, tumor marker levels (CEA and CA19-9) decreased transiently during the period of vaccination. Slight reduction of the tumor volume was observed in one patient, which was considered a minor responder. No changes were noted in three patients while the remaining eleven patients experienced tumor progression. Analysis of peripheral blood lymphocytes of one patient using HLA-A24/peptide tetramers revealed an increase in peptide-specific CTL frequency from 0.09% to 0.35% of CD8+ T cells after 4 vaccinations. This phase I clinical study indicates that survivin-2B peptide-based vaccination is safe and should be further considered for potential immune and clinical efficacy in HLA-A24-expression patients with colorectal cancer.

9.
Gan To Kagaku Ryoho ; 29(10): 1801-4, 2002 Oct.
Artigo em Japonês | MEDLINE | ID: mdl-12402433

RESUMO

We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously. A 49-year-old Japanese man who underwent a right hepatectomy for HCC developed tumor recurrence in the liver 19 months after surgery. Abdominal CT revealed multiple metastatic lesions in the liver. He received a combination therapy of 500 mg/day of 5-FU that was given intravenously by continuous infusion and 5 x 10(6) units of IFN-alpha, given three times weekly. The treatment resulted in a fall in serum PIVKA-II (protein induced by vitamin K antagonism) levels from 337 mAU/ml to 65 mAU/ml and disappearance of tumor stain in enhanced CT. 5-FU is usually administered by arterial infusion in a combination therapy of IFN-alpha and 5-FU. However, 5-FU infusion may be possible intravenously in the combination therapy of IFN-alpha and 5-FU for the treatment of advanced HCC.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Recidiva Local de Neoplasia/tratamento farmacológico , Carcinoma Hepatocelular/cirurgia , Esquema de Medicação , Fluoruracila/administração & dosagem , Humanos , Infusões Intravenosas , Interferon-alfa/administração & dosagem , Neoplasias Hepáticas/cirurgia , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...